Flores BN, Marrero PY, Louvina SJ, Tocto MDS

Language: Spanish
References: 12
Page: 39-45
PDF size: 486.79 Kb.

ABSTRACT

Introduction: leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania; its repercussions can be fatal and cause disability. In the present work, some new compounds with potential antileishmanial activity are identified using in silico studies.
Objective: to create a new database of the evaluated compounds against this parasite and to identify new lead compounds with potential antileishmanial activity through in silico studies.
Methods: the included compounds were compiled from literature and international databases taking the minimum inhibitory concentration to classify them as active and inactive. Molecular descriptors were calculated using STATISTICA 8.0 and DRAGON software; cluster analysis and Euclidean distance were used for training series and time-series prediction. Models were validated and a search for new lead compounds was carried out through virtual screening of databases.
Results: a database of 2145 compounds randomly divided was made up. There were identified 316 potentially antileishmanial compounds after carrying out the virtual screening, among which, known drugs with other pharmacological properties and some natural products with diverse uses were found.
Conclusions: there was created a database of compounds in which the antileishmanial activity was evaluated experimentally, as well as, a model was obtained allowing us to predict the activity of new compounds through virtual screening.

REFERENCES

1. Informe final Segunda Reunión de Gerentes de Programas de leishmaniasis de Las Américas, 8-10 oct. 2013. Ciudad de Panamá: PANAFTOSA - OPS/OMS; 2014 jun.

2. Guía de Atención Integral de Leishmaniasis 2010 (Documento actualizado de Versión final Convenio 256/09) Convenio Cooperación Técnica No. 637 de 2009 Ministerio De La Protección Social. Washington, DC: Organización Panamericana de la Salud; jul. 2010.

3. Fina BL, Lombarte M, Rigalli A. Investigación de un fenómeno natural: ¿estudios in vivo, in vitro o in silico? Actual Osteol. 2013;9(3):294-9.

4. Negwer M. Organic-Chemical Drugs and their Synonyms. Berlin: Akademie 9th, extensively enl. ed. - Weinheim: Wiley-VCH; 2007.

5. Budavari S, O'Neill M, Smith A, Heckelman P, Kinneary J (Merck & Co., Inc.)The Merck Index: An Encyclopedia of Chemicals, Drugs & Biologicals. 12th. ed. New York: Chapman & Hall; 1997.

6. National Center for Biotechnology Information. Antileishmanial activity against antimonyresistant Leishmania infantum MCAN/BR/2002/BH400 promastigote infected in Swiss mouse peritoneal macrophages after 72 hrs. PubChem OPEN Chemistry Database. Bethesda, USA: U.S National Library of Medicine; 2014 https://pubchem.ncbi.nlm.nih.gov/bioassay/744771#section=Top

7. StatSoft, Inc. (2007). STATISTICA (data analysis software system), version 8.0. USA: SAS Institute Inc.; 2008.

8. Perkin E. Software: ChemOffice v, 9.0. Reino Unido: Universidad de Cambridge Soft Corporation; 2003.

9. Todeschini R. Talete srl, DRAGON for Windows (Software for Molecular Descriptor Calculations) v, 5.5 [internet]. Milano (Italy): University of Milano-Bicocca P.za della Scienza; 2007 [citado 10 feb. 2016]. Disponible en: http://www.talete.mi.it

10. The Spectrum Collection [internet]. United States: Micro Source Discovery Systems, Inc.; 2012 [citado 21 mayo 2014]. Disponible en: http://www.msdiscovery.com/spectrum.html

11. Tropsha A. Best Practices for QSAR Model Development, Validation, and Exploitation. Mol Inf. 2010;29:476- 88.

12. World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected tropical diseases: summary. Geneva: WHO; 2013